Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of upadacitinib in adolescents and adults with moderate to severe atopic dermatitis
2018-001383-28Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (3 arms), sponsored by AbbVie Inc. Primary endpoint: vIGA-AD 0 or 1 with at least 2-grade reduction from baseline at Week 16. Started Aug 2018; status: active.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001383-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001383-28.